Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
P/B ratio for Tempest Therapeutics, Inc. (TPST)
P/B ratio as of 2023: 2.53
According to Tempest Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.53. At the end of 2022 the company had a P/B ratio of 0.73.
P/B ratio history for Tempest Therapeutics, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.53 |
| 2022 | 0.73 |
| 2021 | 0.55 |
| 2020 | -0.01 |
| 2019 | 1.58 |
| 2018 | 0.17 |
| 2017 | 0.17 |
| 2016 | 0.45 |
| 2015 | 2.09 |
| 2014 | 18.10 |
| 2013 | 4.96 |
| 2012 | 0.00 |